Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMC

Quality of life changes in patients suffering from knee osteoarthritis treated with bone marrow aspirate concentrate, platelet-rich plasma and hyaluronic acid injections

Dulic O., Abazovic D., Matijevic S., Rasovic P., Obradovic M., Bjelobrk M.

Clinical Trial with a reported sample of 175 on Knee Osteoarthritis, Osteoarthritis, published in Regen Med (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Regen Med (2025)
Reported sample size
175
Source database
Europe PMC
PMID
40028743
PMCID
PMC11951690
DOI
10.1080/17460751.2025.2472589
NCT
NCT03825133
Citations
1

Abstract (original English)

Background This study aimed to compare the effects of different treatments on quality of life in knee osteoarthritis patients. It focused on three therapies: bone marrow aspirate concentrate (BMAC), platelet-rich plasma (PRP), and hyaluronic acid (HA). Methodology The trial was conducted at a single center with 175 patients over a 12-month period with the knee OA, KL grade II-IV. Outcomes were measured using the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) and SF-36 scales, which assess physical and emotional well-being. Linear mixed models (LMMs) were used to analyze which treatment had the most positive impact on quality of life. Results Patients treated with BMAC showed the most substantial improvement, particularly in physical health and mobility ( p ≤ 0,001). PRP outperformed HA in some aspects, but BMAC consistently led to greater gains. The most notable enhancements were seen in areas like role limitations due to physical health and overall physical functioning. Conclusions The study suggested that BMAC treatment may contribute to improved quality of life in patients with knee osteoarthritis, particularly in terms of physical function. The correlation between WOMAC and SF-36 scores supports these findings, indicating a potential role for BMAC in enhancing mobility. Clinical trial registration NCT03825133 (ClinicalTrials.gov).

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansOsteoarthritis, KneeHyaluronic AcidTreatment OutcomeBone Marrow TransplantationQuality of LifeAgedMiddle AgedFemaleMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research